Table 2

Relative potencies of opioid agonists in inhibiting forskolin stimulated intracellular cAMP production for the cloned mouse μ-opioid receptor (μ-WT) and the D114N and μ-TRUNC mutants stably expressed in HEK 293 cells

LigandMuOpioid Receptor/Mutant
μ-WTD114N mutantμ-TRUNC mutant
EC50(nM)Max. inhibition (%)EC50 (nM)Max. inhibition (%)EC50 (nM)Max. inhibition (%)
Morphine2.4  ± 1.171.7  ± 2.8213.  ± 722-a 18.3  ± 11.42-b NDND
Fentanyl0.15  ± 0.181.3  ± 1.90.8  ± 0.12-a 54.3  ± 0.32-b 0.53  ± 0.1487.3  ± 0.32-a
Lofentanil0.03  ± 0.0182.0  ± 1.80.3  ± 0.12-a 74.7  ± 2.30.08  ± 0.184.7  ± 2.1
Sufentanil0.3  ± 0.181.0  ± 1.00.5  ± 0.176.8  ± 2.40.002  ± 0.0012-b 81.7  ± 2.6
Nalbuphine1.5  ± 0.858.0  ± 5.63.1  ± 1.147.7  ± 4.614.4  ± 0.62-b 42.7  ± 6.4
Levorphanol1.0  ± 0.179.0  ± 2.425.3  ± 8.12-a 42.5  ± 6.12-b 0.38  ± 0.152-a 77.7  ± 2.6
  • Agonist inhibition of cAMP accumulation by wild-type, D114N andmu-TRUNC mutant mu receptors stably expressed in HEK 293 cells. For generation of cAMP results, cell monolayers were treated for 30 min at 37°C with growth medium containing 0.5 mM IBMX. After treatment, the medium was replaced with growth medium containing agonist over the concentration range 10−12 to 10−6with 10 μM forskolin, incubated for 5 min at 37°C and then assayed for intracellular cAMP levels as described in “Methods.” The EC50 values were determined by nonlinear regression computer analysis of the dose-response curves generated using GraphPad Prism 2. Maximal inhibition of forskolin-stimulated cAMP accumulation was that obtained at the 1 μM concentration and is expressed as a percentage of the forskolin control. Both results represent the mean ± S.E. of at least three separate experiments, each performed and assayed in duplicate. Statistical significance (P < .05) was determined by a paired Student’s t test.

  • 2-a P < .05 (Student’s t test, compared to wild-type).

  • 2-b P < .01.

  • ND, Not determined.